drugset / Trial / NCT00395057
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
Timeline
- Start
- 2007-01
- Primary completion
- 2008-10
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGN211745 | Small interfering RNA (siRNA) | 100 ug | Intravitreal |
| Subject | AGN211745 | Small interfering RNA (siRNA) | 300 ug | Intravitreal |
| Subject | AGN211745 | Small interfering RNA (siRNA) | 1000 ug | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 500 ug | — |